Consolidation of a genomic epidemiological surveillance network for tuberculosis (REVIGET) in northern and northeastern Brazil: a study protocol
Abstract
Globally, tuberculosis (TB) remains a top cause of death from infectious diseases, with an estimated 1.5 million deaths annually. Given its substantial social and economic burden, TB is a priority in the United Nations 2030 Agenda for Sustainable Development. The WHO's End TB Strategy emphasizes research, innovation, and the rapid implementation of new technologies, such as whole-genome sequencing (WGS), which are pivotal for precision health approaches and drug-resistant TB (DR-TB) surveillance. This study aims to strengthen genomic TB surveillance in the North and Northeast Brazilian regions by applying WGS to study DR-TB cases, training professionals in genomics and bioinformatics, and deploying a national surveillance platform (GEMIBRA). This is an observational, cross-sectional, prospective, quantitative, and qualitative study to be conducted in the states of Pará, Amazonas, Ceará, and Bahia. A total of 500 Mycobacterium tuberculosis complex (MTBC) isolates from DR-TB cases will undergo whole-genome sequencing (WGS), representing 87% of the expected DR-TB cases, including non-tuberculous mycobacteria (NTM) isolates among the DR samples. Data will be analyzed for genotype-phenotype correlations, mutation patterns, and associations with clinical and epidemiological characteristics. Capacity-building activities, including theoretical and hands-on bioinformatics training, will be carried out. The GEMIBRA platform will support data visualization, spatial distribution, and…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.